Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study (2023)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2023.102249

Publication URI: http://dx.doi.org/10.1016/j.eclinm.2023.102249

Type: Journal Article/Review

Parent Publication: eClinicalMedicine